Oragenics, Inc.
OGEN · AMEX
Market closed$0.549600$-0.008200 (-1.47%)After hours $0.556600 · +1.27%
Key statistics
Previous close$0.557800
Open$0.557800
Day high$0.562300
Day low$0.544000
52-week high$1.49
52-week low$0.500000
Market cap2.48M
Volume29.56K
Average volume46.05K
P/E ratio-0.09
Forward P/E—
EPS-6.11
Dividend yield0.00%
Market context
Why it moved
OGEN's modest decline today appears to reflect routine selling pressure and low trading volume in the absence of any significant company-specific catalysts, with the stock drifting lower amid broader market conditions.
What is happening
Recent company-specific developments and publisher coverage.
GlobeNewswire · July 7, 2026Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrollingwww.marketscreener.com · July 6, 2026Oragenics, Inc. Announces Appointment of John Spencer to Chief Financial Officer, Effective July 1, 2026Pluang · May 19, 2026Oragenics to present at Sidoti’s Micro-Cap Virt...GlobeNewswire · May 18, 2026ORAGENICS PROVIDES INVESTOR UPDATEPluang · May 18, 2026Oragenics advances Phase IIa trial of ONP-002 a...Moomoo · May 7, 2026Oragenics Inc - to Receive Exclusive LicenseClinical Trials Arena · May 6, 2026Oragenics opens second site for ONP-002 Phase IIa trialInvesting.com · July 1, 2025Oragenics stock tumbles after announcing $20 million preferred stock offering Mt Newswire · July 7, 2026Oragenics Says All Three Australian Concussion Trial Sites Enrolling Patients Benzinga · May 8, 2026Oragenics Q1 EPS $(0.51) Up From $(3.60) YoY Benzinga · May 7, 2026Oragenics Signs LOI To License Certain Disease Indications Of CardioDialysis, Blood Purification Technology, From Sigyn Therapeutics Benzinga · April 20, 2026Oragenics Says 2 Patients And 8 Study Drug Doses Administered In Ongoing Phase Iia Clinical Trial Evaluating ONP-002, Lead Candidate For Treatment Of Mild Traumatic Brain Injury Benzinga · April 13, 2026Oragenics Doses First Patient In Phase IIa Clinical Trial of ONP-002 Benzinga · March 12, 2026Oragenics Completes First Site Initiation Visit For Its Phase IIa Clinical Study Of ONP-002 In Australia Benzinga · March 11, 2026Oragenics Explores Acquisition Of Additional Assets In Central Nervous System Space; No Definitive Agreements Signed Benzinga · March 10, 2026Oragenics Receives Approval From Australia's Human Research Ethics Committee To Start Phase IIa Clinical Study Of ONP-002 For Concussion Treatment